Alaunos Therapeutics, Inc.
TCRT
$2.08
$0.010.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 18.28% | -23.03% | |||
| Gross Profit | -19.27% | 23.67% | |||
| SG&A Expenses | 6.56% | -23.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.21% | -23.34% | |||
| Operating Income | -11.58% | 23.59% | |||
| Income Before Tax | -12.65% | 22.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.65% | 22.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.65% | 22.95% | |||
| EBIT | -11.58% | 23.59% | |||
| EBITDA | -10.90% | 23.70% | |||
| EPS Basic | -20.21% | 19.10% | |||
| Normalized Basic EPS | -34.46% | 27.67% | |||
| EPS Diluted | -20.21% | 19.10% | |||
| Normalized Diluted EPS | -34.46% | 27.67% | |||
| Average Basic Shares Outstanding | -16.23% | 6.55% | |||
| Average Diluted Shares Outstanding | -16.23% | 6.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||